Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Eligible patients with metastatic pancreatic cancer will be treated with dual agent
monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with
gemcitabine